跳至主要内容
临床试验/NCT06186765
NCT06186765
进行中(未招募)
不适用

Prospective, Non-randomized, Multicenter Clinical Evaluation of the Recharge Free Axonics SNM System (Model 4101)

Axonics, Inc.16 个研究点 分布在 3 个国家目标入组 144 人2023年12月8日

概览

阶段
不适用
干预措施
Axonics SNM System (Model 4101)
疾病 / 适应症
Urinary Urge Incontinence (UUI)
发起方
Axonics, Inc.
入组人数
144
试验地点
16
主要终点
Performance/Effectiveness - Improvement in Quality of Life scoring (OAB)
状态
进行中(未招募)
最后更新
17天前

概览

简要总结

Multicenter, prospective, non randomized, single arm evaluation of patients with overactive bladder (OAB) and/or fecal incontinence (FI) employing the Axonics recharge free SNM System.

详细描述

A clinical evaluation to comply with new European Medical Device Regulations (EU MDR) guidelines. Multicenter, prospective, non-randomized, single arm study for OAB and/or FI to assess the safety and performance of the Food and Drug Administration (FDA) approved Axonics recharge free sacral neuromodulation (SNM) System, INS Model 4101. The product is currently marketed under the name F15.

注册库
clinicaltrials.gov
开始日期
2023年12月8日
结束日期
2027年12月1日
最后更新
17天前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

发起方
Axonics, Inc.
责任方
Sponsor

入排标准

入选标准

  • 18 years or older
  • Primary indication of overactive bladder (OAB) (urinary urgency incontinence (UUI)/ urinary frequency (UF)) or fecal incontinence (FI) who are not candidates for, or who have failed conservative treatment
  • Willing and capable to provide written informed consent and agrees to comply with specified evaluations at clinical investigational sites and attend all follow-up assessments for up to 1 year.

排除标准

  • Any significant medical condition that is likely to interfere with procedures, device operation, or likely to confound evaluation of endpoints (exclusion of neurological conditions such as multiple sclerosis)
  • Any psychiatric or personality disorder that is likely to interfere with procedures at the discretion of the participating physician; this may include poor understanding or compliance with requirements
  • Previously underwent an external sacral neuromodulation (SNM) trial and was deemed a non-responder or was previously implanted with a sacral neuromodulation device and did not get therapeutic benefit (a non-responder)
  • History of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone
  • A female who is breastfeeding
  • A female with a positive urine pregnancy test

研究组 & 干预措施

Single Arm - product does not have Communauté Européenne (CE) Mark in Europe

Observational

干预措施: Axonics SNM System (Model 4101)

结局指标

主要结局

Performance/Effectiveness - Improvement in Quality of Life scoring (OAB)

时间窗: 3 months

International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement.

Performance/Effectiveness - Improvement in Fecal Incontinence Survey

时间窗: 3 months

Cleveland Clinic Florida - Fecal Incontinence Score (CCF-FIS): includes 5 items (solid, liquid, gas, wears pad and lifestyle alteration) and 5 frequencies (never = 0, rarely = 1, sometimes = 2, usually = 3, always = 4). Scores range from 0 for full continence to 20 for complete incontinence. A higher score is indicative of the severity of fecal incontinence.

Adverse event reporting (Safety)

时间窗: 3 months

Device-related, procedure-related and all serious adverse events

Performance/Effectiveness - Improvement in Quality of Life scoring (OAB)

时间窗: 3 months

International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life (ICIQ-OABqol): questions in each subscale are scored by a summed range of 0 to 100, with a higher score indicating better quality of life. Overall score ≥ 10 points from baseline to follow-up is indicative of a clinically meaningful improvement.

Performance/Effectiveness - Improvement in Fecal Incontinence Survey

时间窗: 3 months

Cleveland Clinic Florida - Fecal Incontinence Score (CCF-FIS): includes 5 items (solid, liquid, gas, wears pad and lifestyle alteration) and 5 frequencies (never = 0, rarely = 1, sometimes = 2, usually = 3, always = 4). Scores range from 0 for full continence to 20 for complete incontinence. A higher score is indicative of the severity of fecal incontinence.

Adverse event reporting (Safety)

时间窗: 3 months

Device-related, procedure-related and all serious adverse events

次要结局

  • Performance/Effectiveness - Improvement in Quality of Life scoring (OAB)(1 year)
  • Performance/Effectiveness - Improvement in Fecal Incontinence Survey(1 year)
  • Adverse event reporting (Safety)(1 year)
  • Performance/Effectiveness - Improvement in Quality of Life scoring (OAB)(1 year)
  • Adverse event reporting (Safety)(1 year)
  • Performance/Effectiveness - Improvement in Fecal Incontinence Survey(1 year)
  • Performance/Effectiveness - Improvement in Quality of Life Survey (FI)(3 months, 6 months, 1 year)

研究点 (16)

Loading locations...

相似试验